![]() |
Name |
1-(3,5-Dihydroxyphenyl)-2-propanol
|
Molecular Formula | C9H12O3 | |
IUPAC Name* |
5-(2-hydroxypropyl)benzene-1,3-diol
|
|
SMILES |
CC(CC1=CC(=CC(=C1)O)O)O
|
|
InChI |
InChI=1S/C9H12O3/c1-6(10)2-7-3-8(11)5-9(12)4-7/h3-6,10-12H,2H2,1H3
|
|
InChIKey |
AIISKGPIMSRMOR-UHFFFAOYSA-N
|
|
Synonyms |
Orcinotriol; 1-(3,5-Dihydroxyphenyl)-2-propanol; BS-1271
|
|
CAS | NA | |
PubChem CID | 85247152 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 168.19 | ALogp: | 1.2 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 60.7 | Aromatic Rings: | 1 |
Heavy Atoms: | 12 | QED Weighted: | 0.626 |
Caco-2 Permeability: | -4.567 | MDCK Permeability: | 0.00001490 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.231 |
Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.983 |
30% Bioavailability (F30%): | 0.978 |
Blood-Brain-Barrier Penetration (BBB): | 0.084 | Plasma Protein Binding (PPB): | 40.47% |
Volume Distribution (VD): | 2.53 | Fu: | 61.03% |
CYP1A2-inhibitor: | 0.772 | CYP1A2-substrate: | 0.518 |
CYP2C19-inhibitor: | 0.102 | CYP2C19-substrate: | 0.102 |
CYP2C9-inhibitor: | 0.053 | CYP2C9-substrate: | 0.938 |
CYP2D6-inhibitor: | 0.256 | CYP2D6-substrate: | 0.663 |
CYP3A4-inhibitor: | 0.143 | CYP3A4-substrate: | 0.208 |
Clearance (CL): | 14.937 | Half-life (T1/2): | 0.888 |
hERG Blockers: | 0.038 | Human Hepatotoxicity (H-HT): | 0.109 |
Drug-inuced Liver Injury (DILI): | 0.028 | AMES Toxicity: | 0.021 |
Rat Oral Acute Toxicity: | 0.053 | Maximum Recommended Daily Dose: | 0.466 |
Skin Sensitization: | 0.873 | Carcinogencity: | 0.026 |
Eye Corrosion: | 0.125 | Eye Irritation: | 0.972 |
Respiratory Toxicity: | 0.044 |